



EXHIBIT C

PATENT
Docket No. 235.0020 0101

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):	TARLETON et al.)	Group Art Unit:	Unassigned
)		
Serial No.:	09/518,156)	Examiner:	Unassigned
)		
Filed:	2 March 2000)		
)		
For:	PROPHYLACTIC AND THERAPEUTIC IMMUNIZATION AGAINST PROTOZOAN INFECTION AND DISEASE			

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with the continuing duty of candor and good faith that is to be demonstrated before the United States Patent and Trademark Office (USPTO), the materials enclosed herewith are brought to the attention of the Examiner as possibly being of interest in connection with the above-identified patent application. Consideration of these materials is respectfully requested.

Pursuant to the provisions of MPEP §609, Applicants further request that a copy of the 1449 form, marked as being considered and initialed by the Examiner, be returned with the next Official Communication.

As there has been no Office Action on the merits, Applicants believe there is no additional fee due. However, in the event any fee is due, please charge any additional fees or credit any overpayment to Deposit Account No. 13-4895.

COPY

Supplemental Information Disclosure Statement

Page 2 of 2

Serial No. 09/518,156


Filed: 2 March 2000

For: PROPHYLACTIC AND THERAPEUTIC IMMUNIZATION AGAINST PROTOZOAN INFECTION AND DISEASE

The Examiner is invited to contact Applicants' Representatives at the below-listed telephone number, if they can be of any assistance during prosecution of the present application.

CERTIFICATE UNDER 37 C.F.R. 1.8:


The undersigned hereby certifies that this paper is being deposited in the United States Postal Service, as first class mail, in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on this 27th day of October, 2000.


Victoria A. Sandberg

Date

27 October 2000

Respectfully submitted,
Rick Tarleton et al.
By their Representatives,
Mueting, Raasch & Gebhardt, P.A.
P.O. Box 581415
Minneapolis, MN 55458-1415
Telephone (612)305-1220
Facsimile (612)305-1228

By: 
Victoria A. Sandberg
Reg. No. 41,287
Direct Dial (612)305-1226

**INFORMATION
DISCLOSURE
STATEMENT**

Applicant(s): TARLETON et al.

Serial No.: 09/518,156

Filing Date: 2 March 2000

Group: Unassigned

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	SubClass	Filing Date If Appropriate
	NONE					

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	SubClass	Translation
					Yes No
NONE					

OTHER DOCUMENTS (Including Authors, Title, Date, Pertinent Papers, etc.)

	Higuchi et al., "The Role of Active Myocarditis in the Development of Heart Failure in Chronic Chagas' Disease: A Study Based on Endomyocardial Biopsies," <u>Clin. Cardiol.</u> 10(11):665-670 (1987).
	Low et al., "Identification of the 83-kDa Amastigote Surface Protein of Trypanosoma cruzi as a Member of the Sialidase Family and a Target of CTL Responses," Abstract and Poster, Joint Meeting of the Amer. Soc. Tropical Med. Hyg., Amer. Soc. Parasitologists, Baltimore, MD 6 pages (1996).
	Santos et al., "The Identification and Molecular Characterization of a Trypanosoma cruzi Amastigote Surface Protein, Asp-1, a Member of the Trans-Sialidase Gene Superfamily," Abstract and Poster, Joint Meeting of the Amer. Soc. Biochemistry and Molecular Biology, Amer. Soc. Investigative Pathology, and Amer. Assoc. Immunologists, June 1-6, New Orleans, LA, <u>FASEB J.</u> , 10(6):A1083 9 pages (1996).
	World Health Organization, "Special programme for research and training in tropical diseases, Sixth Programme Report, Chapter Six: Chagas' Disease," TDR/PR-6/83.6 - CHA, UNDP/World Bank/WHO (1983).
	World Health Organization, "Special programme for research and training in tropical diseases; Meeting on the development of trypanocidal compounds for the sterilization of blood," Geneva, December 13-14, TDR/CHA/BS/84.3, UNDP/World Bank/WHO (1984).

EXAMINER

Date Considered

*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Based on Form PTO-FB-A820 Patent and Trademark Office, U.S. Department of Commerce (Also form PTO-1449)

RECEIVED
JAN 07 2002

TECH CENTER 1600/2900

COPY